Novo Nordisk will soon resubmit Tresiba to the FDA, earlier than once expected. The escalated timeline provided a substantial boost to Novo's shares, but the news adds pressure to Sanofi's new CEO since Tresiba targets Lantus, the French drugmaker's top seller.
Sanofi Pasteur counts pediatric vaccines among its 5 key areas, and it's bolstering its offerings in the field with Wednesday's FDA approval of the Quadracel vaccine.
What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get.
Sanofi is hoping to spring forward with a new marketing campaign for OTC Nasacort.
Sanofi is shipping more than 200 researchers to German outsourcing firm Evotec as it finally gets out of a French R&D site whose fate led to a squabble with the local government, reaching a compromise the company believes will leave all sides appeased.
Sanofi's Indian affiliate, Shantha Biotechnics, says it's ready to deliver 37 million doses of its low-cost pediatric pentavalent vaccine, Shan5.
Sanofi can go back to the FDA with Lyxumia. The French drugmaker got good news from a cardiovascular outcomes study, required by the FDA before it would approve the diabetes drug.
While a long list of biopharma companies have been dropping the ax on R&D staffers in recent weeks and months, some of the top execs being shown the exit are finding that new doors are opening as fast as old positions are whisked away. Today, Tal Zaks underscored the bright side of restructuring, being named chief medical officer at Moderna Therapeutics a month after he was among 100 oncology R&D staffers who were ushered out at Sanofi in a recent reorganization.
A new generation of cardiovascular drugs has proved itself capable of lowering bad cholesterol across dozens of Phase III trials, but many physicians are holding out to see whether doing so can meaningfully improve patients' lives. In an early peek at some long-term data, one such injected therapy from Amgen halved the risk of major cardiovascular problems after one year of treatment, bolstering the case for the whole class of drugs.
The French city of Marseille has staked its claim for a corner of the booming immunotherapy R&D ecosystem. And the plan has some big-name backers, with Sanofi and Innate Pharma both signing up as founders of the MI-mAbs immunotherapy research center in the city.